By Professor Peter Ian Croucher

Journal articles

Terpos E; Anagnostopoulos A; Heath D; Kastritis E; Christoulas D; Anagnostopoulos N; Roussou M; Tsionos K; Croucher P; Dimopoulos MA, 2006, 'The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.', Blood, 108, pp. 3541 - 3541, http://dx.doi.org/10.1182/blood.v108.11.3541.3541

Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K, 2006, 'Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: A study in the 5TMM model', Clinical and Experimental Metastasis, 23, pp. 291 - 300, http://dx.doi.org/10.1007/s10585-006-9038-6

Politou MC; Heath DJ; Rahemtulla A; Szydlo R; Anagnostopoulos A; Dimopoulos MA; Croucher PI; Terpos E, 2006, 'Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation', International Journal of Cancer, 119, pp. 1728 - 1731, http://dx.doi.org/10.1002/ijc.22033

Karadag A; Zhou M; Croucher PI, 2006, 'ADAM-9 (MDC-9/meltrin-γ), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the α vβ5 integrin', Blood, 107, pp. 3271 - 3278, http://dx.doi.org/10.1182/blood-2005-09-3830

Rabin N; Kyriakou C; Pizzey A; Buckle C; Prideaux M; Croucher P; Nathwani A; Yong K, 2006, '663. Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Reverse Osteoclast Activation in a Xenogeneic Murine Model of Multiple Myeloma', Molecular Therapy, 13, pp. S256 - S256, http://dx.doi.org/10.1016/j.ymthe.2006.08.740

Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL, 2005, 'Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - A role in tumour cell survival?', Breast Cancer Research and Treatment, 92, pp. 207 - 215, http://dx.doi.org/10.1007/s10549-005-2419-8

Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B, 2005, 'The 5T2MM murine model of multiple myeloma: maintenance and analysis.', Methods in molecular medicine, 113, pp. 191 - 205

Kartsogiannis V; Ly C; Zhou H; Gallagher O; Buckle C; De Leenheer E; Vanderkerken K; Ng KW; Martin T; gillespie M; Croucher P, 2005, 'Expression of RANKL, OPG, PTHrP and OCIL in multiple myeloma are influenced by the tumor cells` proximity to bone', Journal of Bone and Mineral Research, 20, pp. S211 - S211

Croucher PI, 2004, 'The RANKL system and the development of tumor-induced bone disease: Lessons from pre-clinical models', Journal of Musculoskeletal Neuronal Interactions, 4, pp. 285 - 292

Eaton CL; Wells JM; Holen I; Croucher PI; Hamdy FC, 2004, 'Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer', Prostate, 59, pp. 304 - 310, http://dx.doi.org/10.1002/pros.20016

De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI, 2004, 'Evidence of a role for RANKL in the development of myeloma bone disease', Current Opinion in Pharmacology, 4, pp. 340 - 346, http://dx.doi.org/10.1016/j.coph.2004.03.011

Van Valckenborgh E; Croucher PI; De Raeve H; Carron C; De Leenheer E; Blacher S; Devy L; Noël A; De Bruyne E; Asosingh K; Van Riet I; Van Camp B; Vanderkerken K, 2004, 'Multifunctional role of matrix metalloproteinases in multiple myeloma: A study in the 5T2MM mouse model', American Journal of Pathology, 165, pp. 869 - 878, http://dx.doi.org/10.1016/S0002-9440(10)63349-4

Menu E; Asosingh K; Van Riet I; Croucher P; Van Camp B; Vanderkerken K, 2004, 'Myeloma cells (5TMM) and their interactions with the marrow microenvironment', Blood Cells, Molecules, and Diseases, 33, pp. 111 - 119, http://dx.doi.org/10.1016/j.bcmd.2004.04.012

Vanderkerken K; Asosingh K; Croucher P; Van Camp B, 2003, 'Multiple myeloma biology: Lessons from the 5TMM models', Immunological Reviews, 194, pp. 196 - 206, http://dx.doi.org/10.1034/j.1600-065X.2003.00035.x

Shipman CM; Croucher PI, 2003, 'Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells', Cancer Research, 63, pp. 912 - 916

Croucher PI; De Raeve H; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K, 2003, 'Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival', Journal of Bone and Mineral Research, 18, pp. 482 - 492, http://dx.doi.org/10.1359/jbmr.2003.18.3.482

Vanderkerken K; De Leenheer E; Shipman C; Asosingh K; Willems A; Van Camp B; Croucher P, 2003, 'Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma', Cancer Research, 63, pp. 287 - 289

Ashcroft AJ; Cruickshank SM; Croucher PI; Perry MJ; Rollinson S; Lippitt JM; Child JA; Dunstan C; Felsburg PJ; Morgan GJ; Carding SR, 2003, 'Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin', Immunity, 19, pp. 849 - 861, http://dx.doi.org/10.1016/S1074-7613(03)00326-1

Croucher P; Jagdev S; Coleman R, 2003, 'The anti-tumor potential of zoledronic acid', Breast, 12, http://dx.doi.org/10.1016/S0960-9776(03)80161-3

Holen I; Croucher PI; Hamdy FC; Eaton CL, 2002, 'Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells', Cancer Research, 62, pp. 1619 - 1623

Holen I; Eaton C; Hamdy F; Croucher P, 2002, 'Production of osteoprotegerin by prostate cancer cells suppresses trial induced apoptosis', European Urology Supplements, 1, pp. 54 - 54, http://dx.doi.org/10.1016/s1569-9056(02)80203-2

Wells J; Holen I; Croucher P; Hamdy F; Eaton C, 2002, 'Serum osteoprotegerin levels are increased in hormone resistant prostate cancer patients', European Urology Supplements, 1, pp. 159 - 159, http://dx.doi.org/10.1016/s1569-9056(02)80621-2

Croucher PI; Shipman CM; Lippitt J; Perry M; Asosingh K; Hijzen A; Brabbs AC; Van Beek EJR; Holen I; Skerry TM; Dunstan CR; Russell GR; Van Camp B; Vanderkerken K, 2001, 'Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma', Blood, 98, pp. 3534 - 3540, http://dx.doi.org/10.1182/blood.V98.13.3534

Holen I; Drury NL; Hargreaves PG; Croucher PI, 2001, 'Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells', British Journal of Haematology, 114, pp. 414 - 421, http://dx.doi.org/10.1046/j.1365-2141.2001.02963.x

Salomo M; Gimsing P; Shipman CM; Croucher PI, 2001, 'Bisphosphonates and in vivo models of multiple myeloma [3] (multiple letters)', British Journal of Haematology, 113, pp. 841 - 842, http://dx.doi.org/10.1046/j.1365-2141.2001.02804-3.x

Russell G; Mueller G; Shipman C; Croucher P, 2001, 'Clinical disorders of bone resorption.', Novartis Foundation symposium, 232

Asosingh K; De Raeve H; Croucher P; Goes E; Van Riet I; Van Camp B; Vanderkerken K, 2001, 'In vivo homing and differentiation characteristics of mature (CD45⁻) and immature (CD45⁺) 5T multiple myeloma cells', Experimental Hematology, 29, pp. 77 - 84, http://dx.doi.org/10.1016/S0301-472X(00)00625-1

Zhou M; Graham R; Russell G; Croucher PI, 2001, 'MDC-9 (adam-9/meltrin γ) functions as an adhesion molecule by binding the αvβ5 integrin', Biochemical and Biophysical Research Communications, 280, pp. 574 - 580, http://dx.doi.org/10.1006/bbrc.2000.4155

Jagdev SP; Coleman RE; Shipman CM; Rostami-H. A; Croucher PI, 2001, 'The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel', British Journal of Cancer, 84, pp. 1126 - 1134, http://dx.doi.org/10.1054/bjoc.2001.1727

Shipman CM; Croucher PI; Vanderkerken K, 2001, 'Reply to salomo and gimsing', British Journal of Haematology, 113, pp. 842 - 842, http://dx.doi.org/10.1046/j.1365-2141.2001.02804-4.x

Jagdev SP; Croucher PI; Coleman RE, 2001, 'The effects of intravenous bisphosphonate treatment on the bone microenvironment in patients with breast cancer and bone metastases', European Journal of Cancer, 37, pp. S129 - S129, http://dx.doi.org/10.1016/s0959-8049(01)80965-5

Shipman CM; Vanderkerken K; Rogers MJ; Lippitt JM; Asosingh K; Hughes DE; Van Camp B; Russell RGG; Croucher PI, 2000, 'The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma', British Journal of Haematology, 111, pp. 283 - 286, http://dx.doi.org/10.1046/j.1365-2141.2000.02310.x

Karadag A; Oyajobi BO; Apperley JF; Graham R; Russell G; Croucher PI, 2000, 'Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts', British Journal of Haematology, 108, pp. 383 - 390, http://dx.doi.org/10.1046/j.1365-2141.2000.01845.x

Karadag A; Scutt AM; Croucher PI, 2000, 'Human myeloma cells promote the recruitment of osteoblast precursors: Mediation by interleukin-6 and soluble interleukin-6 receptor', Journal of Bone and Mineral Research, 15, pp. 1935 - 1943, http://dx.doi.org/10.1359/jbmr.2000.15.10.1935

Apperley JF; Croucher PI, 1999, 'Bisphosphonates in multiple myeloma', Pathologie Biologie, 47, pp. 178 - 181

Sati HIA; Greaves M; Apperley JF; Russell RGG; Croucher PI, 1999, 'Expression of interleukin-1β and tumour necrosis factor-α in plasma cells from patients with multiple myeloma', British Journal of Haematology, 104, pp. 350 - 357, http://dx.doi.org/10.1046/j.1365-2141.1999.01193.x

Croucher PI; Wang F; Hargreaves PG, 1999, 'Interleukin-6 Receptor (IL-6R) Shedding: A Role for Members of the ADAM Family', Biochemical Society Transactions, 27, pp. A23 - A23, http://dx.doi.org/10.1042/bst027a023a

Croucher PI; Apperley JF, 1998, 'Bone disease in multiple myeloma', British Journal of Haematology, 103, pp. 902 - 910, http://dx.doi.org/10.1046/j.1365-2141.1998.01082.x

Shipman CM; Croucher PI; Russell RGG; Helfrich MH; Rogers MJ, 1998, 'The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway', Cancer Research, 58, pp. 5294 - 5297

Hargreaves PG; Wang F; Antcliff J; Murphy G; Lawry J; Russell RGG; Croucher PI, 1998, 'Human myeloma cells shed the interleukin-6 receptor: Inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor', British Journal of Haematology, 101, pp. 694 - 702, http://dx.doi.org/10.1046/j.1365-2141.1998.00754.x

Sati HIA; Apperley JF; Greaves M; Lawry J; Gooding R; Russell RGG; Croucher PI, 1998, 'Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance', British Journal of Haematology, 101, pp. 287 - 295, http://dx.doi.org/10.1046/j.1365-2141.1998.00687.x

Shipman CM; Rogers MJ; Apperley JF; Russell RGG; Croucher PI, 1998, 'Anti-tumour activity of bisphosphonates in human myeloma cells', Leukemia and Lymphoma, 32, pp. 129 - 138, http://dx.doi.org/10.3109/10428199809059253

Wu E; Croucher PI; McKie N, 1997, 'Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies', Biochemical and Biophysical Research Communications, 235, pp. 437 - 442, http://dx.doi.org/10.1006/bbrc.1997.6714

McKie N; Edwards T; Dallas DJ; Houghton A; Stringer B; Graham R; Russell G; Croucher PI, 1997, 'Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes', Biochemical and Biophysical Research Communications, 230, pp. 335 - 339, http://dx.doi.org/10.1006/bbrc.1996.5957

Shipman CM; Rogers MJ; Apperley JF; Russell RGG; Croucher PI, 1997, 'Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity', British Journal of Haematology, 98, pp. 665 - 672, http://dx.doi.org/10.1046/j.1365-2141.1997.2713086.x

McKie N; Dallas DJ; Edwards T; Apperley JF; Russell RGG; Croucher PI, 1996, 'Cloning of a novel membrane-linked metalloproteinase from human myeloma cells', Biochemical Journal, 318, pp. 459 - 462, http://dx.doi.org/10.1042/bj3180459

Vedi S; Croucher PI; Garrahan NJ; Compston JE, 1996, 'Effects of hormone replacement therapy on cancellous bone microstructure in postmenopausal women', Bone, 19, pp. 69 - 72, http://dx.doi.org/10.1016/8756-3282(96)00108-1

Compston JE; Vedi S; Croucher PI; Garrahan NJ, 1996, 'Effects of hormone replacement therapy on cancellous bone microstructure in postmenopausal women', Bone, 19, pp. 136 - 136, http://dx.doi.org/10.1016/s8756-3282(96)90752-8

Compston JE; Croucher PI; Garrahan NJ; Yamaguchi K; Lindsay P; Shaw R, 1994, 'O4. Effect of gonadotrophin-releasing hormone analogues on bone structure', Bone, 15, pp. 450 - 450, http://dx.doi.org/10.1016/8756-3282(94)90827-3

Croucher PI; Vedi S; Motley RJ; Garrahan NJ; Stanton MR; Compston JE, 1994, 'P17. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease', Bone, 15, pp. 121 - 121, http://dx.doi.org/10.1016/8756-3282(94)90940-7

Back to profile page